Biomarker & Intervention Discovery
Pancreatic Cancer
Pharmacologically actionable gene targets, therapeutic agents ranked by evidence tier, and active clinical trials.
NIH funding$288MFY2025 · RCDC estimate
Funding levelModerate
Spontaneous remissionEssentially zero; one of the highest cancer mortality rates; 5-year survival ~12% overall; only 15-20% have resectable…
Best-intervention remissionResectable: surgery (Whipple) + FOLFIRINOX adjuvant: 54.4 months median OS (PRODIGE 24, vs 35.0 months gemcitabine)…
Gap sizeVery large — minimal survival improvement for most patients over past 20 years; imaging and liquid biopsy for early…
Primary barrierbiological + access (early detection)
Full remission profile →
Remission & chronicity
Spontaneous remission
Essentially zero; one of the highest cancer mortality rates; 5-year survival ~12% overall; only 15-20% have resectable disease at diagnosis
Best-intervention remission
Resectable: surgery (Whipple) + FOLFIRINOX adjuvant: 54.4 months median OS (PRODIGE 24, vs 35.0 months gemcitabine); BRCA-mutant metastatic: olaparib maintenance after platinum-based: 7.4 vs 3.8 months PFS (POLO); neoadjuvant chemotherapy: may convert 20-30% of borderline-resectable to resectable
Gap size
Very large — minimal survival improvement for most patients over past 20 years; imaging and liquid biopsy for early detection is the biggest opportunity
Primary barrier
biological + access (early detection)
Pancreatic cancer is detected late (70-80% at Stage III-IV) due to absence of early symptoms and screening; CA19-9 is insufficiently sensitive/specific for early detection; BRCA1/2 and other HRR mutation testing is not universal; KRAS G12D/G12V targeted agents represent a genuine pipeline advance
Biomarker Targets & Therapeutic Agents
Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC.
Agents ranked: ● Clinical >
● Mechanistic >
● Correlative.
Pipeline results not yet available. Run: python -m biomarker_pipeline.run_for_diseases --skip-llm
Clinical Trials
Recruiting and recently completed trials from ClinicalTrials.gov.
Data retrieved 2026-07-06.
No recent clinical trials found on ClinicalTrials.gov for this condition.
Agents Found By Disease-Level Search
Searched directly from “Pancreatic Cancer” via ClinicalTrials.gov interventions and Open Targets'
disease→drug data — independent of the 0-gene target panel above.
This surfaces agents whose mechanism doesn't route through a curated gene (combination
therapies, standard-of-care drugs, targets outside the panel).
Not yet run. python -m biomarker_pipeline.run_disease_agent_discovery --disease "..."